Research programme: paclitaxel inhalation - Ventaira

Drug Profile

Research programme: paclitaxel inhalation - Ventaira

Latest Information Update: 15 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ventaira Pharmaceuticals
  • Developer National Cancer Institute (USA); Ventaira Pharmaceuticals
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Lung cancer

Most Recent Events

  • 29 Oct 2007 Ventaira Pharmaceuticals has been acquired and merged into Battelle
  • 08 Jan 2004 BattellePharma is now called Ventaira Pharmaceuticals
  • 24 May 2002 Battelle Pulmonary Therapeutics is now called BattellePharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top